Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:actsOn |
opioid agonist
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:ATCCode |
A07DA03
|
| gptkbp:brand |
gptkb:Motofen
|
| gptkbp:CASNumber |
24390-14-5
|
| gptkbp:contraindication |
children under 2 years
patients with obstructive jaundice |
| gptkbp:controlled_substance_schedule_(US) |
Schedule IV (when combined with atropine)
|
| gptkbp:has_legal_status_(US) |
prescription only
|
| gptkbp:hasMolecularFormula |
C28H29NO2·HCl
|
| https://www.w3.org/2000/01/rdf-schema#label |
difenoxin hydrochloride
|
| gptkbp:is_salt_of |
gptkb:difenoxin
|
| gptkbp:IUPACName |
1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine hydrochloride
|
| gptkbp:marketed_in_combination_with |
gptkb:atropine_sulfate
|
| gptkbp:metabolism |
difenoxine
|
| gptkbp:relatedTo |
gptkb:diphenoxylate
gptkb:loperamide |
| gptkbp:sideEffect |
nausea
drowsiness dry mouth |
| gptkbp:usedFor |
antidiarrheal agent
|
| gptkbp:bfsParent |
gptkb:Motofen
|
| gptkbp:bfsLayer |
7
|